셀메드 (CELLMED)

  • 제13권14호
  • /
  • Pages.14.1-14.9
  • /
  • 2023
  • /
  • 3022-6805(pISSN)
  • /
  • 3022-6791(eISSN)
셀메드 세포교정의약학회 (Cellmed Orthocellular Medicine and Pharmaceutical Association)
권호 표지
DOI QR코드

DOI QR Code

Cognitive Improvement Effect of Resplex Alpha A in the Scopolamine-induced Mouse Model

  • 투고 : 2023.11.30
  • 심사 : 2023.11.30
  • 발행 : 2023.11.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Administration of Scopolamine can be considered a psychopharmacological model of Alzheimer's disease (AD). We made an animal model of Alzheimer's disease (AD) by administering Scopolamine to Blab/c mice. In this study, we investigated the effects of Resplex Alpha on memory impairment and cognitive function in mice in a mouse animal model of Scopolamine-induced memory impairment. Through Y-mazed and passive avoidance behavioral assays, we observed that Resplex Alpha recovered Scopolamine-induced short-term memory and cognitive functions. The results of our study imply that Resplex Alpha may be beneficial in the prevention of Alzheimer's disease (AD).

키워드

참고문헌

  1. Chuong, N. N.; Trung, B. H.; Luan, T. C.; Hung, T. M.; Dang, N. H.; Dat, N. T. Anti-amnesic effect of alkaloid fraction from Lycopodiella cernua (L.) Pic. Serm. on scopolamine-induced memory impairment in mice. Neurosci Lett 2014, 575, 42-46. DOI: 10.1016/j.neulet.2014.05.031 From NLM.
  2. Becker, R.; Giacobini, E.; Elble, R.; McIlhany, M.; Sherman, K. Potential pharmacotherapy of Alzheimer disease. A comparison of various forms of physostigmine administration. Acta Neurol Scand Suppl 1988, 116, 19-32. DOI: 10.1111/j.1600-0404.1988.tb07983.x From NLM.
  3. Taraschenko, O. D.; Barnes, W. G.; Herrick-Davis, K.; Yokoyama, Y.; Boyd, D. L.; Hough, L. B. Actions of tacrine and galanthamine on histamine-N-methyltransferase. Methods Find Exp Clin Pharmacol 2005, 27 (3), 161-165. DOI: 10.1358/mf.2005.27.3.890872 From NLM.
  4. Farlow, M.; Gracon, S. I.; Hershey, L. A.; Lewis, K. W.; Sadowsky, C. H.; Dolan-Ureno, J. A controlled trial of tacrine in Alzheimer's disease. The Tacrine Study Group. Jama 1992, 268 (18), 2523-2529. From NLM. https://doi.org/10.1001/jama.1992.03490180055026
  5. Watkins, P. B.; Zimmerman, H. J.; Knapp, M. J.; Gracon, S. I.; Lewis, K. W. Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. Jama 1994, 271 (13), 992-998. From NLM. https://doi.org/10.1001/jama.1994.03510370044030
  6. Park, S. M.; Ki, S. H.; Han, N. R.; Cho, I. J.; Ku, S. K.; Kim, S. C.; Zhao, R. J.; Kim, Y. W. Tacrine, an oral acetylcholinesterase inhibitor, induced hepatic oxidative damage, which was blocked by liquiritigenin through GSK3-beta inhibition. Biol Pharm Bull 2015, 38 (2), 184-192. DOI: 10.1248/bpb.b14-00430 From NLM.
  7. Houghton, P. J.; Ren, Y.; Howes, M. J. Acetylcholinesterase inhibitorsfrom plants and fungi. Nat Prod Rep 2006, 23 (2), 181-199. DOI: 10.1039/b508966m From NLM.
  8. Oh, M. H.; Houghton, P. J.; Whang, W. K.; Cho, J. H. Screening of Korean herbal medicines used to improve cognitive function for anti-cholinesterase activity. Phytomedicine 2004, 11 (6), 544-548. DOI: 10.1016/j.phymed.2004.03.001 From NLM.
  9. Hasanein, P.; Mahtaj, A. K. Ameliorative effect of rosmarinic acid on scopolamine-induced memory impairment in rats. Neurosci Lett 2015, 585, 23-27. DOI: 10.1016/j.neulet.2014.11.027 From NLM.
  10. Palit, P.; Mukherjee, D.; Mandal, S. C. Reconstituted mother tinctures of Gelsemium sempervirens L. improve memory and cognitive impairment in mice scopolamine-induced dementia model. J Ethnopharmacol 2015, 159, 274-284. DOI: 10.1016/j.jep.2014.09.008 From NLM.
  11. Buglio, D. S.; Marton, L. T.; Laurindo, L. F.; Guiguer, E. L.; Araujo, A. C.; Buchaim, R. L.; Goulart, R. A.; Rubira, C. J.; Barbalho, S. M. The Role of Resveratrol in Mild Cognitive Impairment and Alzheimer's Disease: A Systematic Review. J Med Food 2022, 25 (8), 797-806. DOI: 10.1089/jmf.2021.0084 From NLM.
  12. Weinmann, S.; Roll, S.; Schwarzbach, C.; Vauth, C.; Willich, S. N. Effects of Ginkgo biloba in dementia: systematic review and meta-analysis. BMC Geriatr 2010, 10, 14. DOI: 10.1186/1471-2318-10-14 From NLM.
  13. Tan, M. S.; Yu, J. T.; Tan, C. C.; Wang, H. F.; Meng, X. F.; Wang, C.; Jiang, T.; Zhu, X. C.; Tan, L. Efficacy and adverse effects of ginkgo biloba for cognitive impairment and dementia: a systematic review and meta-analysis. J Alzheimers Dis 2015, 43 (2), 589-603. DOI: 10.3233/jad-140837 From NLM.
  14. DeFeudis, F. V.; Drieu, K. Ginkgo biloba extract (EGb 761) and CNS functions: basic studies and clinical applications. Curr Drug Targets 2000, 1 (1), 25-58. DOI: 10.2174/1389450003349380 From NLM.
  15. Liu, X.; Hao, W.; Qin, Y.; Decker, Y.; Wang, X.; Burkart, M.; Schotz, K.; Menger, M. D.; Fassbender, K.; Liu, Y. Long-term treatment with Ginkgo biloba extract EGb 761 improves symptoms and pathology in a transgenic mouse model of Alzheimer's disease. Brain Behav Immun 2015, 46, 121-131. DOI: 10.1016/j.bbi.2015.01.011 From NLM.
  16. Farina, N.; Llewellyn, D.; Isaac, M.; Tabet, N. Vitamin E for Alzheimer's dementia and mild cognitive impairment. Cochrane Database Syst Rev 2017, 4 (4), Cd002854. DOI: 10.1002/14651858.CD002854.pub5 From NLM.
  17. Deng, X.; Zhao, S.; Liu, X.; Han, L.; Wang, R.; Hao, H.; Jiao, Y.; Han, S.; Bai, C. Polygala tenuifolia: a source for anti-Alzheimer's disease drugs. Pharm Biol 2020, 58 (1), 410-416. DOI: 10.1080/13880209.2020.1758732 From NLM.
  18. Choi, M.; Lee, Y.; Cho, S. H. Angelica tenuissima Nakai Ameliorates Cognitive Impairment and Promotes Neurogenesis in Mouse Model of Alzheimer's Disease. Chin J Integr Med 2018, 24 (5), 378-384. DOI: 10.1007/s11655-017-2812-2 From NLM.
  19. Li, H.; Kim, J.; Tran, H. N. K.; Lee, C. H.; Hur, J.; Kim, M. C.; Yang, H. O. Extract of Polygala tenuifolia, Angelica tenuissima, and Dimocarpus longan Reduces Behavioral Defect and Enhances Autophagy in Experimental Models of Parkinson's Disease. Neuromolecular Med 2021, 23 (3), 428-443. DOI: 10.1007/s12017-020-08643-x From NLM.
  20. Renner, U. D.; Oertel, R.; Kirch, W. Pharmacokinetics and pharmacodynamics in clinical use of scopolamine. Ther Drug Monit 2005, 27 (5), 655-665. DOI: 10.1097/01.ftd.0000168293.48226.57